GENENTECH, INC.

Tryptase Inhibitor Fails to Meet Primary Endpoint in Asthma Exacerbation Trial

- A Phase 2a clinical trial of MTPS9579A, an anti-tryptase antibody, did not significantly reduce the time to first asthma exacerbation event compared to placebo. - The study involved 134 patients with moderate-to-severe asthma, who received either 1800 mg of MTPS9579A or placebo every four weeks for 48 weeks. - Phase 1c trial data indicated that MTPS9579A concentrations were significantly lower in bronchial lining fluid compared to nasal lining fluid, suggesting insufficient drug saturation. - Despite the negative results, researchers emphasize tryptase remains a relevant target for asthma therapies due to its role in airway inflammation and hyperresponsiveness.